Patents by Inventor Hamilton D. Dickson

Hamilton D. Dickson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL
    Publication number: 20260068886
    Abstract: Provided herein are compositions, compounds, and methods for modulating the levels of target proteins in insects and insect cells. The compounds may contain one or more protein targeting moieties that each independently bind a protein that is expressed by an insect cell; one or more ligase targeting moieties that each independently bind a ubiquitin ligase that is functional in the insect cell; and a linker covalently bonded to the one or more protein targeting moieties and the one or more ligase targeting moieties; or a salt or a solvate thereof.
    Type: Application
    Filed: August 31, 2023
    Publication date: March 12, 2026
    Applicant: Oerth Bio LLC
    Inventors: Jason D. Speake, Christopher C. Ladner, Hamilton D. Dickson, John G. Catalano, Kelly D. D. Broccio, Melina M. R. Lillich, Samuel G. Gattis, Steven C. Bremmer
  • 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended)
    Publication number: 20250066361
    Abstract: Compounds, specifically hepatitis B virus and/or hepatitis D virus inhibitors, more specifically compounds that inhibit HBe antigen and HBs antigen in a subject, for the treatment of viral infections, and methods of preparing and using such compounds.
    Type: Application
    Filed: November 11, 2024
    Publication date: February 27, 2025
    Inventors: John G. CATALANO, Pek Yoke Chong, Hamilton D. Dickson, Martin R. Leivers, Jason Gordon Weatherhead
  • 5,6,7,7a-tetrahydrocyclopenta[f]pyrido[1,2-h][1,7]naphthyridin-11(4bH)-one compounds and methods of use
    Patent number: 12221444
    Abstract: Compounds, specifically hepatitis B virus and/or hepatitis D virus inhibitors, more specifically compounds that inhibit HBe antigen and HBs antigen in a subject, for the treatment of viral infections, and methods of preparing and using such compounds.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: February 11, 2025
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: John G. Catalano, Pek Yoke Chong, Hamilton D. Dickson, Martin R. Leivers, Jason Gordon Weatherhead
  • Chemical Compounds
    Publication number: 20220144834
    Abstract: Compounds, specifically hepatitis B virus and/or hepatitis D virus inhibitors, more specifically compounds that inhibit HBe antigen and HBs antigen in a subject, for the treatment of viral infections, and methods of preparing and using such compounds.
    Type: Application
    Filed: October 25, 2021
    Publication date: May 12, 2022
    Inventors: John G. CATALANO, Pek Yoke CHONG, Hamilton D. DICKSON, Martin R. LEIVERS, Jason Gordon WEATHERHEAD
  • CHEMICAL COMPOUNDS
    Publication number: 20200255428
    Abstract: Compounds, specifically hepatitis B virus and/or hepatitis D virus inhibitors, more specifically compounds that inhibit HBe antigen and HBs antigen in a subject, for the treatment of viral infections, and methods of preparing and using such compounds.
    Type: Application
    Filed: October 5, 2018
    Publication date: August 13, 2020
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: John G. CATALANO, Pek Yoke CHONG, Hamilton D. DICKSON, Martin R. LEIVERS, Jason Gordon WEATHERHEAD
  • Modulators of indoleamine 2,3-dioxygenase
    Patent number: 10472336
    Abstract: Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of HIV; including the prevention of the progression of AIDS and general immunosuppression.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: November 12, 2019
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Pek Yoke Chong, Martha Alicia De La Rosa, Hamilton D. Dickson, Wieslaw Mieczyslaw Kazmierski, Vicente Samano, Vincent Wing-Fai Tai
  • Modulators of indoleamine 2,3-dioxygenase
    Patent number: 10358427
    Abstract: Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of HIV; including the prevention of the progression of AIDS and general immunosuppression.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: July 23, 2019
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Pek Yoke Chong, Martha Alicia De La Rosa, Hamilton D. Dickson, Wieslaw Mieczyslaw Kazmierski, Vicente Samano, Vincent Wing-Fai Tai
  • MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE
    Publication number: 20180290988
    Abstract: This invention is directed to photoluminescent compounds based on rhodamine dyes with green emission and uses thereof for photoluminescence based devices.
    Type: Application
    Filed: September 22, 2016
    Publication date: October 11, 2018
    Inventors: Pek Yoke CHONG, Martha Alicia DE LA ROSA, Hamilton D. DICKSON, Wieslaw Mieczyslaw KAZMIERSKI, Vicente SAMANO, Vincent Wing-Fai TAI
  • Compounds And Methods For Enhancing Innate Immune Responses
    Publication number: 20140249143
    Abstract: Provided are certain compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections.
    Type: Application
    Filed: October 19, 2012
    Publication date: September 4, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Anna Lindsey Banka, Janos Botyanszki, Eric Gregory Burroughs, John George Catalano, Wendy Huang Chern, Hamilton D. Dickson, Margaret J. Gartland, Robert Hamatake, Hans Hofland, Jesse Daniel Keicher, Christopher Brooks Moore, John Bradford Shotwell, Matthew David Tallant, Jean-Philippe Therrien, Shihyun You